Stocks and Investing Stocks and Investing
Tue, October 24, 2017
Mon, October 23, 2017

Christopher Raymond Initiated (BIIB) at Buy and Held Target at $390 on, Oct 23rd, 2017


Published on 2024-10-25 23:47:52 - WOPRAI, Christopher Raymond
  Print publication without navigation


Christopher Raymond of Piper Sandler, Initiated "Biogen Inc." (BIIB) at Buy and Held Target at $390 on, Oct 23rd, 2017.

Christopher has made no other calls on BIIB in the last 4 months.



There are 10 other peers that have a rating on BIIB. Out of the 10 peers that are also analyzing BIIB, 4 agree with Christopher's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Brian Abrahams of "RBC Capital" Initiated at Hold and Held Target at $319 on, Friday, September 15th, 2017
  • Jeffrey Silber of "BMO Capital" Maintained at Hold with Increased Target to $377 on, Wednesday, September 13th, 2017
  • Carter Gould of "UBS" Maintained at Hold with Increased Target to $285 on, Wednesday, July 26th, 2017
  • Eun Yang of "Jefferies" Initiated at Hold and Held Target at $310 on, Tuesday, July 11th, 2017


These are the ratings of the 6 analyists that currently disagree with Christopher


  • Ying Huang of "B of A Securities" Maintained at Strong Buy with Increased Target to $365 on, Wednesday, October 18th, 2017
  • Salim Syed of "Mizuho" Upgraded from Hold to Strong Buy on, Tuesday, October 17th, 2017
  • Thomas Shrader of "Stifel" Upgraded from Hold to Strong Buy on, Tuesday, October 17th, 2017
  • Matthew Harrison of "Morgan Stanley" Upgraded from Hold to Buy on, Thursday, October 5th, 2017
  • Terence Flynn of "Goldman Sachs" Upgraded at Strong Buy on, Wednesday, August 16th, 2017
  • Andrew Peters of "Deutsche Bank" Initiated at Strong Buy and Held Target at $315 on, Friday, June 23rd, 2017
Contributing Sources